RCS - IXICO plc - Appointment of Senior Therapeutic Advisor

IXICOAnnouncement

31/01/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220131:nRSe0535Aa&default-theme=true

RNS Number : 0535A  IXICO plc  31 January 2022

IXICO plc

("IXICO" or the "Company")

 

Appointment of Senior Therapeutic Advisor

Leading International Clinical trial expert, Dr. Lynne Hughes, appointed as
Advisor to the Company

 

IXICO plc (AIM: IXI), the medical imaging advanced analytics company
delivering intelligent insights in neuroscience, announces that it has
appointed Dr. Lynne Hughes, an international neurology clinical trial research
expert, to IXICO as a Senior Therapeutic Advisor to the Company. Dr. Hughes,
who brings more than 35 years of experience in the global clinical research
field, will use her deep neurology R&D expertise and knowledge of the
global neurology landscape to advise and support IXICO's management in the
development of the Company's therapeutic strategy. In particular, Dr. Hughes
will focus on determining adjacent therapeutic areas into which IXICO can
diversify into and expand the deployment of its proprietary neuroimaging CRO
and AI data analytics services.

 

Dr. Hughes most recently held the position of Vice President and Global Head,
Medical and Therapeutic Strategy, Neurology at IQVIA. In a 23-year tenure at
IQVIA, Dr. Hughes managed and was senior oversight on more than 450 trials
including 125 trials relating to Alzheimer's disease (many of which she
designed and managed from concept through to Phase III) and more than 75
trials in Parkinson's disease and 65 trials in Multiple Sclerosis.

 

Dr. Hughes currently sits on multiple neurology therapeutic focused advisory
boards, steering executive committees.  She co-chairs one of the three global
taskforces of the G20/World Economic Forum Alzheimer's Collaboration
(DAVOS-DAC), the taskforce charged with expediting drug development in
Alzheimer's disease, is a senior advisor to the Global Alzheimer's Platform
foundation (GAP) and is a member of the NIA/NIH taskforce for recruitment into
AD trials and the development of the US National Framework. In addition, Dr.
Hughes has worked with various research organisations including the Gates
Foundation, Alzheimer's Association, Alzheimer's Research UK, ADI and is a
member of the G7 and G20 World Dementia Councils.

 

Dr. Lynne Hughes commented: "Specialist neuroimaging is now a critical, integral and growing requirement of clinical trials in neurological diseases such as Alzheimer's Disease, Parkinson's Disease and Multiple Sclerosis. With an increasing interest by the global pharmaceutical industry in precision medicine, there is also considerable R&D investment in the development of new imaging biomarkers across a wide range of rare neurological diseases such as Huntington's Disease and Friedrich's Ataxia. As such, it is essential to ensure that the imaging provider selected by the clinical trial sponsor is at the forefront of imaging technology and advanced data analytics. The team at IXICO are world renowned neuroimaging experts with cutting edge AI algorithm development capabilities and so I am delighted to be working with the team in supporting their current and future clients in executing their CNS strategy to the highest standards."
 

Giulio Cerroni, CEO of IXICO, commented: "We are delighted to welcome Dr.
Hughes to IXICO. Our Company's purpose is to support our clients in their
tireless efforts to bring potential treatments to patients suffering from
neurological disorders. The appointment of Dr. Hughes brings significant
additional experience and understanding to enable IXICO to further strengthen
and scale our capabilities as the trusted neuroimaging partner of choice to
the global pharmaceutical industry."

 

 

 

 

For further information please contact:

 

 IXICO plc                                             +44 (0)20 3763 7498
 Giulio Cerroni, Chief Executive Officer

 Grant Nash, Chief Financial Officer

 Cenkos Securities PLC (Nominated adviser and sole broker)              +44 (0)20 7397 8900
 Giles Balleny / Max Gould (Corporate Finance)
 Michael F Johnson / Russell Kerr (Sales)

 Walbrook PR Ltd   Tel: 020 7933 8780 or IXICO@walbrookpr.com

 Paul McManus / Alice Woodings /     Mob: 07980 541 893 / 07407 804 654 /

 Lianne Applegarth                   07584 391 303

 

About IXICO | Advanced Analytics | Intelligent Insights.

IXICO is dedicated to delivering insights in neuroscience to help transform
the advancement of investigational therapies for neurological diseases, such
as Huntington's disease, Parkinson's disease and Alzheimer's disease. The
Company's purpose is to advance medicine and human health by turning data into
clinically meaningful information, providing valuable new insights in
neuroscience by supporting pharmaceutical companies across all phases of CNS
clinical research. IXICO's goal is to be a leading advocate of artificial
intelligence in medical image analysis.

 

IXICO has developed and deployed breakthrough data analytics, at scale,
through its remote access technology platform, to improve the return on
investment in drug development and reduce risk and uncertainty in clinical
trials for the Company's pharmaceutical clients.

 

More information is available on www.IXICO.com (http://www.IXICO.com)  and
follow us on Twitter @IXICOnews

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABPMLTMTATBLT